Medtronic and its technology partner IBM Watson Health have announced a new feature for the Sugar.IQ personal diabetes assistant app, dubbed IQcast.
Using artificial intelligence (AI) technology from IBM Watson Health, the feature aims to predict the likelihood of an individual experiencing a low glucose event within an upcoming 1-4 hour window.
Medtronic diabetes group medical & clinical affairs senior director Robert Vigersky said: “Simply put, IQcast acts like a weather forecast for people with diabetes so they can better prepare for their day.
“By predicting the likelihood of a low glucose event from anywhere between 1 and 4 hours in advance, IQcast empowers people on multiple daily injections (MDI) with insights so they can live their life with greater freedom and better health.”
IBM Watson Health deputy chief health officer Lisa Latts said: “Hypoglycemia, or ‘going low’, is one of the most acute and frightening events that a person living with diabetes can experience.
“Fueled by the right data, AI and machine learning can play a powerful role in helping to alleviate the burden of diabetes and the worry of a hypoglycemic event, and we’ve built the new IQcast features with this goal in mind.”
Medtronic and IBM Watson Health leveraged their combined expertise in diabetes, AI and analytics to develop the IQcast feature as part of the Sugar.IQ personal diabetes assistant app. Both companies have been dedicated to advancing the science behind predicting potential hypoglycemia since the beginning of the partnership.
The IQcast feature analyzes multiple signals to assess whether someone with diabetes has a low, medium, or high likelihood of going low over the next 1-4 hours. The degree of predictive accuracy that IQcast is able to achieve increases as a low blood sugar1 event becomes more imminent.
The Sugar.IQ assistant reveals patterns that may be hard to see so that someone with diabetes gains meaningful, personalized insights. These insights show people using MDI how lifestyle choices impact their diabetes management and their time spent with glucose in the target range (70-180 mg/dL).
The app uses AI and advanced analytics to give users a full picture of their current levels and provides individualized guidance in understanding and managing daily diabetes management decisions, so that people on MDI have more freedom to enjoy life.
The Sugar.IQ app is available to users of the Medtronic Guardian Connect system, the first smart standalone CGM system designed to empower people with diabetes using MDI with actionable tools to help them get ahead of low and high glucose levels – not just react to them.
With customized predictive alerts in the Guardian Connect system up to 60 minutes before a low or high event and within a one to four hour window before a low event withthe Sugar.IQ assistant, Medtronic provides people with more tools to help them stay in range than any other CGM system.
As presented at the American Diabetes Association Scientific Sessions (2017, 2018), when using both the Guardian Connect smart CGM system in conjunction with the Sugar.IQ app, users have shown the ability to achieve an extra 36 minutes per day in a healthy glucose range of 70-180 mg/dL, including 30 minutes less time in hyperglycemia and 6 less minutes in hypoglycemia.
The Sugar.IQ app is available for iOS-based mobile devices in the U.S.
Source: Company Press Release